Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388154 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
A Phase 2 study of Endometrial Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 3
- Study locations
NCT00388154 is a Phase 2 study of Endometrial Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT00388154, a Phase 2 study of Endometrial Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 3
- Study locations
Study Summary
Primary Objective: * To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer. Secondary Objective: * To determine the nature and degree of toxicity of the combination of gemcitabine and cisplatin in this cohort of patients.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
Study Locations (3)
Texas
- St. Lukes Episcopal Hospital - Houston
- UT MD Anderson Cancer Center - Houston
- The Woman's Hospital of Texas - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2004-08 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00388154
The ClinicalTrials.gov registry entry for NCT00388154 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (96% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cisplatin is the first listed.
NCT00388154 reports 3 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00388154 about?
NCT00388154 is a clinical study titled "Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer". Primary Objective: * To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer. Secondary Objective: * To determine the nature and degree of toxicity of the combination of gemcitabine and cisplati...
What is the current status of trial NCT00388154?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2004-08. Estimated completion is 2013-11.
What conditions does trial NCT00388154 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT00388154?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00388154?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00388154 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.